Phathom Pharmaceuticals (PHAT) Interest & Investment Income (2019 - 2026)

Phathom Pharmaceuticals (PHAT) has 8 years of Interest & Investment Income data on file, last reported at $1.7 million in Q1 2026.

• On a quarterly basis, Interest & Investment Income fell 34.24% year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was $6.1 million, a 54.47% decrease from a year earlier, with the FY2025 full-year figure at $7.0 million, down 53.53% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $1.7 million, up from $1.2 million in the prior quarter.
• Over the last five years, Interest & Investment Income for PHAT reached as high as $4.3 million in Q1 2024 and fell as low as $7000.0 in Q1 2022.
• Historically, Interest & Investment Income has averaged $2.0 million across 5 years, with a median of $1.7 million in 2026.
• Across the five-year window, Interest & Investment Income jumped 21350.0% in 2022 and tumbled 65.7% in 2025, its largest moves.
• Year by year, Interest & Investment Income stood at $1.3 million in 2022, then jumped by 160.14% to $3.3 million in 2023, then increased by 4.84% to $3.5 million in 2024, then tumbled by 65.7% to $1.2 million in 2025, then surged by 44.19% to $1.7 million in 2026.
• Per Business Quant data, the three most recent Interest & Investment Income figures were $1.7 million in Q1 2026, $1.2 million in Q4 2025, and $1.4 million in Q3 2025.